v3.26.1
Revenues and other income - Additional Information (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Mar. 17, 2025
EUR (€)
Jul. 07, 2023
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2025
EUR (€)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Dec. 31, 2021
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2023
USD ($)
Jul. 07, 2023
EUR (€)
Jul. 07, 2023
USD ($)
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues       € 29,643,000 € (11,609,000) € 30,058,000          
Net loss for the period       23,961,000 68,132,000            
Refund liabilities       3,530,000 35,613,000            
Increase in contract liability       18,100,000              
Other income       € 2,950,000 4,419,000 6,150,000          
Research tax credit utilization period       3 years              
Decrease of research tax credit       € 500,000              
Research tax credit       2,800,000 3,300,000 3,900,000          
Subsidies       78,000 89,000 229,000          
Services                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues       22,682,000 (17,534,000) 29,750,000          
Research and Development                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues       21,800,000              
Other Services                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues       900,000              
Other sales                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues       6,961,000 5,924,000 308,000          
Nanobiotix Corp.                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Decrease of research tax credit       300,000              
Nanobiotix S.A.                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Decrease of research tax credit       200,000              
Janssen                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Collaboration agreement, upfront payment license fee | $   $ 30,000                  
Collaboration agreement, success-based payment | $   $ 1,800,000                  
Proceeds receivable due to milestone completion | $               $ 20,000      
Revenues         (1,600,000) (1,600,000)          
Deal value                   € 2,700,000,000  
Increase in contract liability € 18,100,000                    
Constrained Transaction Price | $                 $ 50,000    
Janssen | Services                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues         (23,400,000) (29,600,000)          
Net loss for the period         19,300,000            
Janssen | Research and Development                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues         4,000,000.0            
Janssen | Technology transfer                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues         1,800,000 100,000          
Refund liabilities       € 35,600,000              
Janssen | Other sales                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues         5,900,000 300,000          
Janssen | Major ordinary share transactions                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Potential development and commercial milestones payments                   105,000,000  
Deal value                   2,600,000,000  
Janssen | Top of Range                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Potential development and commercial milestones payments | $                     $ 650,000
Collaboration agreement, compensation per indication | $                     220,000
Janssen | Top of Range | Nanobiotix Corp.                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Collaboration agreement, compensation per indication                   € 220,000,000 $ 220,000
LianBio, NBTXR3                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Minimum threshold to provide additional know-how to third party under collaboration agreement       80.00%              
Upfront payment received | $     $ 20,000       $ 20,000        
Supply Services       € 100,000 1,000,000.0 2,000,000.0          
LianBio, NBTXR3 | Maximum                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Potential development and commercial milestones payments | $     $ 205,000                
LianBio, NBTXR3 and Cetuximab                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Other income           1,600,000          
Global Trial Clinical Agreement                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Other income         778,000            
NONORAY-312                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Potential development and commercial milestones payments € 105,000,000                    
Janssen Pharmaceutica BV                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues       21,800,000              
Asia Licensing Agreement                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Increase in contract liability       € 18,100,000              
JNJ-1900 (NBTXR3)                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Other income         € 237,000 € 334,300